Skip to content
Bored Studies
RecruitingPhase 3

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Glaukos Corporation · NCT07495852

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
510
US sites recruiting
1
Study start
February 17, 2026
Record last updated
March 30, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Being studied: Gen 2 Travoprost Intracameral Implant; Timolol eye drops 0.5%; Sham Procedure; placebo eye drops

Conditions: Glaucoma

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye

Exclusion Criteria

  • Prior incisional glaucoma surgery in the study eye
  • Prior argon laser trabeculoplasty (ALT) in the study eye
  • Prior minimally invasive glaucoma (MIGS) surgery in the study eye

Recruiting US locations

  • Glaukos Investigative Site

    Dothan, AL 36301

    Site contact: Luis Vargas, MD · 949-739-8749 · ClinicalResearch@glaukos.com

Study contacts (from the official record)

  • Study Director · 949-739-8749 · ClinicalResearch@glaukos.com
All heart & blood pressure studies in Alabama →
Trial to Evaluate the Safety and Efficacy of the Second Generation… (NCT07495852) | Bored Studies